Kuppermann, Baruch D.

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Heier, J. S., Lad, E. M., Holz, F. G., Rosenfeld, P. J., Guymer, R. H., Boyer, D., Grossi, F., Baumal, C. R., Korobelnik, J.-F., Slakter, J. S., et al. (2023) · The Lancet

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 520

Cardiovascular disease, its risk factors and treatment and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary Study

Klein, R., Deng, Y., Klein, B. E. K., Hyman, L., Seddon, J., Frank, R. N., Wallace, R. B., Hendrix, S. L., Kuppermann, B. D., Langer, R. D., et al. (2007) · American Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal Imaging and Analysis

Cited by 142

Brolucizumab and immunogenicity

Sharma, A., Kumar, N., Parachuri, N., Sharma, R., Bandello, F., Kuppermann, B. D., & Loewenstein, A. (2020) · Eye

Retinal Diseases and TreatmentsBiosimilars and Bioanalytical Methods

Cited by 51

Semaglutide and the risk of diabetic retinopathy—current perspective

Sharma, A., Parachuri, N., Kumar, N., Saboo, B., Tripathi, H. N., Kuppermann, B. D., & Bandello, F. (2022) · Eye

Retinal Diseases and TreatmentsDiabetes Treatment and Management

Cited by 43